Effects of angiotensin-converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats

被引:12
|
作者
Zhang, RY
Wang, LF [1 ]
Zhang, L
Meng, XN
Li, SJ
Wang, WR
机构
[1] Harbin Med Coll, Clin Hosp 1, Dept Cardiol, Harbin 150001, Peoples R China
[2] Harbin Med Coll, Clin Hosp 1, Dept Pathol, Harbin 150001, Peoples R China
关键词
Smad; ventricular remodeling; angiotensin converting enzyme inhibitor; angiotensin II type I receptor blocker;
D O I
10.1097/00029330-200604020-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Transforming growth factor (TGF) beta(1)-Smads signal plays an important role in cardiac remodeling following myocardial infarction (MI). In addition, both angiotensin converting enzyme inhibitor (ACEI) and angiotensin II type I receptor blocker (ARB) can effectively prevent left ventricular remodeling. The current study focused on whether the combination of ACEI and ARB is more beneficial for preventing ventricular remodeling and whether Smad proteins mediate this beneficial effect. Methods MI was induced by ligating the left anterior descending coronary artery in rats. Twenty-four hours after ligation, the survived rats were randomly divided into five groups and treated for 8 weeks: placebo group, ACEI group (benazepril 10 mg (.) kg(-1) (.) d(-1)), ARB group (irbesartan 50 mg (.) kg-(1 .) d(-1)), ACEI + ARB group (benazepril 10 mg (.) kg (.) d(-1) + irbesartan 50 mg (.) kg (.) d(-1)) and control group (sham-operated rats). After 8 weeks, we examined the following indexes: the ratio of ventricular weight to body weight,(VW/BW), left ventricular end diastolic dimension (LVDd), ejection fraction (EF), fractional shortening (FS), ratio of E-wave to A-wave velocity, collagen of noninfarcted zone, the mRNA expression of TGF beta(1), Smad 2, and Smad 3 by RT-PCR in noninfarcted zone, the protein expression of Smad 2 and Smad 3 in noninfarcted zone by Western blot. Results VW/BW significantly increased in the placebo groups compared with that in the control group (P < 0.01). This increase was limited in ACEI, ARB, and combined groups (P < 0.01 compared with placebo group). There was no significant difference among the three actively treated groups. Collagen was increased in placebo group (5.68 +/- 0.5)% compared with that in control group (P < 0.01). ACEI, ARB and combined treatment attenuated this increase of collagen [(4.3 +/- 0.5)%, (3.5 +/- 0.5)%, (3.2 +/- 0.4)%] in comparison with that in placebo group (P < 0.01 respectively). Combined treatment showed more significant effect on collagen deposition. EF and FS significantly decreased, LVDd and E/A significantly increased in placebo group compared with that in control group (P < 0.01 respectively). ACEI, ARB and combined treatment ameliorated these indexes (P < 0.01 compared with placebo group). The mRNA expression of TGF beta(1), Smad 2, and Smad 3 (0.700 +/- 0.045, 0.959 +/- 0.037 and 0.850 +/- 0.051) increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective in decreasing TGF beta(1) and Smad mRNA expression than ACEI treatment (P < 0.01). The expression of Smad 2 and Smad 3 protein increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective than ACEI alone (P < 0.01). Conclusions TGF beta(1)-Smads signal activation is correlated with ventricular remodeling following MI. ACEI and ARB treatment prevents ventricular remodeling by inhibiting expression of Smad 2 and Smad 3.. ARB and combined treatment are more effective than ACEI alone.
引用
收藏
页码:649 / 655
页数:7
相关论文
共 50 条
  • [2] Effects of angiotensin converting enzyme inhibitor,angio-tensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats
    ZHANG Ruiying WANG Lanfeng ZHANG Lei MENG Xiangning LI Shaojun and WANG Wuru Department of Cardiology Department of Pathology First Clinical Hospital Harbin Medical University Harbin China
    ChineseMedicalJournal, 2006, (08) : 649 - 655
  • [3] Effects of combination therapy of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker
    Idrizi, A
    Gjata, M
    Barbullushi, M
    Koroshi, A
    Tase, M
    Sadiku, E
    Hoti, K
    JOURNAL OF HYPERTENSION, 2005, 23 : S398 - S398
  • [4] Effects of angiotensin II receptor blockade, angiotensin-converting enzyme inhibition, and their combination on postinfarction ventricular remodeling
    Mankad, S
    Reichek, N
    Singh, D
    Rogers, WJ
    Kramer, CM
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 325S - 325S
  • [5] ANTIPROTEINURIC AND RENOPROTECTIVE EFFECTS OF COMBINATION THERAPY WITH AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND AN ANGIOTENSIN RECEPTOR BLOCKER
    Sadiku, Edita
    Idrizi, Alma
    Gjata, Margarita
    Barbullushi, Myftar
    Hoti, Klit
    Tase, Mihal
    Koroshi, Alketa
    NEPHROLOGY, 2005, 10 : A136 - A136
  • [6] Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats
    Yamada, T
    Kuno, A
    Ogawa, K
    Tang, MX
    Masuda, K
    Nakamura, S
    Ando, T
    Okamoto, T
    Ohara, H
    Nomura, T
    Joh, T
    Shirai, T
    Itoh, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (01): : 36 - 45
  • [7] Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on ventricular defibrillation threshold
    Kamochi, Hideyuki
    Yamanouchi, Yoshio
    Saku, Keijiro
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2006, 29 (07): : 747 - 752
  • [8] Beneficial Effects of Combination Therapy with Angiotensin II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor on Vascular Endothelial Function
    Satoshi Morimoto
    Kei Maki
    Yasuko Aota
    Takao Sakuma
    Toshiji Iwasaka
    Hypertension Research, 2008, 31 : 1603 - 1610
  • [9] Beneficial Effects of Combination Therapy with Angiotensin II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor on Vascular Endothelial Function
    Morimoto, Satoshi
    Maki, Kei
    Aota, Yasuko
    Sakuma, Takao
    Iwasaka, Toshiji
    HYPERTENSION RESEARCH, 2008, 31 (08) : 1603 - 1610
  • [10] Optimal dose of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection
    Hou, Fan Fan
    Zhou, Qiu Gen
    NEPHROLOGY, 2010, 15 : 57 - 60